LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

LLY

1,053.95

+2.58%↑

JNJ

213.94

+1.18%↑

ABBV

227.32

+1.73%↑

UNH

338.97

-0.71%↓

AZN

91.17

+1.54%↑

Home・Aandelen Lijst・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorGezondheidszorg

17.68 -1.83

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.38

Max

18.09

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.8M -127M
Werknemers	517
EBITDA	-2M -123M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+74.53% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	642M 2.9B
Vorige openingsprijs	19.51
Vorige sluitingsprijs	17.68

Nieuwssentiment

By Acuity

50%

158 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

13.355 / 16.44 Steun & Weerstand

Denali Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 dec 2025, 22:53 UTC

Acquisities, Fusies, Overnames

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dec 2025, 00:04 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dec 2025, 23:46 UTC

Marktinformatie

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dec 2025, 23:36 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dec 2025, 22:38 UTC

Acquisities, Fusies, Overnames

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dec 2025, 22:02 UTC

Acquisities, Fusies, Overnames

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dec 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dec 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dec 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Fortescue to Acquire Remaining 64% of Alta Copper

14 dec 2025, 17:00 UTC

Winsten

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dec 2025, 16:48 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 08:00 UTC

Acquisities, Fusies, Overnames

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dec 2025, 07:00 UTC

Acquisities, Fusies, Overnames

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dec 2025, 00:24 UTC

Acquisities, Fusies, Overnames

Want a Piece Of SpaceX? -- Barrons.com

12 dec 2025, 23:49 UTC

Acquisities, Fusies, Overnames

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dec 2025, 22:52 UTC

Marktinformatie

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dec 2025, 22:32 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 dec 2025, 20:45 UTC

Winsten

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dec 2025, 20:41 UTC

Marktinformatie

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dec 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dec 2025, 19:23 UTC

Winsten

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dec 2025, 18:35 UTC

Acquisities, Fusies, Overnames

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dec 2025, 18:33 UTC

Acquisities, Fusies, Overnames

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dec 2025, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dec 2025, 17:49 UTC

Winsten

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dec 2025, 17:34 UTC

Acquisities, Fusies, Overnames

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer Vergelijking

Prijswijziging

Denali Therapeutics Inc Prognose

Koersdoel

By TipRanks

74.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.38 USD 74.53%

Hoogste 37 USD

Laagste 26 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Denali Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Denali Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

13.355 / 16.44Steun & Weerstand

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

158 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.